Qasim Rizvi, KSQ Therapeutics CEO
July 13, 2023 11:30 AM EDTUpdated 04:57 PM
Startups
Deals

Roche li­cens­es KSQ's PhI can­cer small mol­e­cule, with cash in­fu­sion to help bankroll biotech's TIL cell ther­a­pies

Kyle LaHucik

Senior Reporter

KSQ Ther­a­peu­tics quick­ly lined up an­oth­er Big Phar­ma part­ner­ship, this time al­ly­ing with Roche in on­col­o­gy, and it plans to use the cash wind­fall to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

2024's bio­phar­ma win­ners and losers; Ca­griSe­ma falls short; Mer­ck swings Chi­na GLP-1 deal; and more

A service from the Financial Times